Price (delayed)
$20.78
Market cap
$444.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.28
Enterprise value
$371.97M
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic
There are no recent dividends present for RNAC.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.